A diabetes drug created by Sanofi-Aventis has been granted regulatory approval for release in Europe. The drug will be approved for both children and adolescents to use.
Apidra, the new diabetes drug, will be used for children aged six years and over. The medicine will be generally used in combination with a basal insulin dose. Sanofi are understood to be excited by the decision.
The senior medical director of the diabetes-metabolism franchise, Riccardo Perfetti, reportedly commented: “Sanofi-aventis recognises the many challenges faced by children with diabetes and their families, and is committed to providing paediatric patients and their healthcare providers with new treatment options.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…